Headlines about CELLECT BIOTECH/S (NASDAQ:APOP) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CELLECT BIOTECH/S earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1957356310439 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of NASDAQ:APOP traded up $0.01 during midday trading on Thursday, reaching $7.09. 1,062 shares of the company’s stock were exchanged, compared to its average volume of 71,242. The company has a market capitalization of $39.69 million, a price-to-earnings ratio of -4.86 and a beta of 4.66. CELLECT BIOTECH/S has a fifty-two week low of $6.12 and a fifty-two week high of $13.50.
CELLECT BIOTECH/S (NASDAQ:APOP) last released its quarterly earnings results on Thursday, May 17th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.14. sell-side analysts expect that CELLECT BIOTECH/S will post -1 EPS for the current year.
A number of analysts have issued reports on APOP shares. Zacks Investment Research raised CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, March 20th. ValuEngine raised CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of CELLECT BIOTECH/S in a research report on Tuesday, May 29th.
CELLECT BIOTECH/S Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.